What insulin dosing and titration plan should be used for a 70‑kg adult being discharged on insulin glargine (Lantus) 25 units daily and insulin lispro (Humalog) 8–12 units before meals with a random glucose of 300 mg/dL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Discharge Insulin Regimen for a 70‑kg Adult with Random Glucose 300 mg/dL

Immediately transition from sliding‑scale insulin to a scheduled basal‑bolus regimen with insulin glargine 25 units once daily at bedtime and insulin lispro 8–12 units before each meal, because sliding‑scale monotherapy is condemned by all major diabetes guidelines and achieves target glucose in only ≈38 % of patients versus ≈68 % with basal‑bolus therapy. 1, 2, 3


Critical Problem with Current Regimen

  • A random glucose of 300 mg/dL on discharge indicates complete inadequacy of the current insulin regimen, not merely a need for dose adjustment. 1
  • Sliding‑scale insulin as the sole treatment is explicitly condemned by the American Diabetes Association and other major societies because it reacts to hyperglycemia after it occurs rather than preventing it, leading to dangerous glucose fluctuations. 1, 2, 3
  • Only ≈38 % of patients managed with sliding‑scale alone achieve mean glucose < 140 mg/dL, compared with ≈68 % using a scheduled basal‑bolus regimen. 1, 2, 3

Recommended Discharge Insulin Regimen

Basal Insulin (Glargine/Lantus)

  • Start with 25 units once daily at bedtime (approximately 0.36 units/kg for a 70‑kg patient), which falls within the recommended range of 0.3–0.5 units/kg/day for severe hyperglycemia. 1
  • This dose provides continuous 24‑hour basal coverage to suppress hepatic glucose production between meals and overnight. 1
  • The current 25‑unit dose is reasonable but requires systematic titration to achieve fasting glucose 80–130 mg/dL. 1

Titration Protocol:

  • Increase by 4 units every 3 days if fasting glucose remains ≥180 mg/dL. 1
  • Increase by 2 units every 3 days if fasting glucose is 140–179 mg/dL. 1
  • Stop basal escalation when the dose approaches 0.5 units/kg/day (≈35 units) without achieving targets; at this threshold, intensify prandial insulin instead to avoid "over‑basalization." 1, 4

Prandial Insulin (Lispro/Humalog)

  • Continue 8–12 units before each of the three main meals (breakfast, lunch, dinner), administered 0–15 minutes before eating. 1
  • The current dose range is appropriate for a 70‑kg patient with severe hyperglycemia; the total prandial dose of 24–36 units/day represents approximately 50 % of the total daily insulin requirement. 1

Titration Protocol:

  • Increase each meal dose by 1–2 units (≈10–15 %) every 3 days based on the 2‑hour post‑prandial glucose reading for that specific meal. 1
  • Target post‑prandial glucose < 180 mg/dL. 1
  • Adjust each meal dose independently based on its corresponding post‑meal glucose pattern. 1

Correction (Supplemental) Insulin

  • Add 2 units lispro for pre‑meal glucose > 250 mg/dL. 1
  • Add 4 units lispro for pre‑meal glucose > 350 mg/dL. 1
  • Correction doses must supplement—not replace—the scheduled prandial insulin; they are given in addition to the meal dose. 1, 2

Monitoring Requirements

  • Daily fasting glucose to guide basal insulin adjustments. 1
  • Pre‑meal glucose before each meal to calculate correction doses. 1
  • 2‑hour post‑prandial glucose after each meal to assess prandial adequacy and guide titration. 1
  • Bedtime glucose to evaluate overall daily pattern. 1
  • Reassess insulin doses every 3 days during active titration. 1
  • Check HbA1c every 3 months until stable control is achieved. 1

Foundation Therapy: Metformin

  • Continue or start metformin at 1000 mg twice daily (2000 mg total) unless contraindicated. 1
  • Metformin reduces total insulin requirements by 20–30 % and provides superior glycemic control compared with insulin alone. 1
  • The maximum effective daily dose is up to 2500 mg. 1
  • Do not discontinue metformin when intensifying insulin therapy unless specific contraindications exist (e.g., renal impairment, acute illness). 1

Expected Clinical Outcomes

  • With properly implemented basal‑bolus therapy, ≈68 % of patients achieve mean glucose < 140 mg/dL, compared with ≈38 % on sliding‑scale alone. 1, 2, 3
  • An HbA1c reduction of 2–3 % is achievable within 3–6 months with intensive insulin titration combined with metformin. 1
  • Properly executed basal‑bolus regimens do not increase overall hypoglycemia incidence compared with inadequate sliding‑scale approaches. 1, 2, 3

Hypoglycemia Management

  • Treat any glucose < 70 mg/dL immediately with 15 g of fast‑acting carbohydrate (e.g., 4 glucose tablets or 4 oz juice), recheck in 15 minutes, and repeat if needed. 1
  • If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % before the next administration. 1
  • Never use lispro at bedtime as a sole correction dose, as this markedly raises nocturnal hypoglycemia risk. 1

Critical Pitfalls to Avoid

  • Do not continue sliding‑scale insulin as the sole regimen when glucose repeatedly exceeds 180 mg/dL; this approach is inferior and unsafe. 1, 2, 3
  • Do not delay adding or intensifying prandial insulin when random glucose is 300 mg/dL; this clearly indicates the need for both basal and mealtime coverage. 1
  • Do not increase basal insulin beyond 0.5–1.0 units/kg/day (≈35–70 units) without addressing post‑prandial hyperglycemia, to prevent over‑basalization and hypoglycemia. 1, 4
  • Do not discontinue metformin when starting or intensifying insulin unless contraindicated, as this leads to higher insulin requirements and more weight gain. 1
  • Do not rely solely on correction doses without adjusting scheduled basal and prandial insulin; correction insulin must supplement, not replace, scheduled doses. 1, 2

Patient Education Essentials

  • Hypoglycemia recognition and treatment: consume ≈15 g fast‑acting carbohydrate when glucose < 70 mg/dL, recheck in 15 minutes. 1
  • Proper insulin injection technique and site rotation to prevent lipohypertrophy. 1
  • Self‑monitoring of blood glucose: at least four daily measurements (fasting, pre‑meal, bedtime) during titration. 1
  • "Sick day" management: continue insulin even if not eating, check glucose every 4 hours, maintain hydration. 1
  • Insulin storage and handling: keep unopened vials refrigerated; opened vials can be stored at room temperature for up to 28 days. 1

Follow‑Up Schedule

  • 1–2 weeks post‑discharge: primary‑care or endocrinology visit to assess glucose control and adjust insulin doses. 1
  • Monthly visits until HbA1c falls below 9 %; thereafter every 3 months. 1
  • Urgent endocrinology referral required if HbA1c remains > 9 % after 3–6 months of intensive titration. 1

Related Questions

How do you calculate insulin doses?
What is the recommended dose of Humalog (insulin lispro) to initiate before meals in a patient with uncontrolled type 2 diabetes mellitus (DM) currently on Basaglar (glargine) 0.3 units/kg/day?
What is the appropriate basal-bolus insulin regimen for a 76-kilogram patient using insulin glargine (Lantus) and glulisine (Apidra)?
What is a suitable prescriber template for sliding scale insulin in a patient with diabetes?
What is the recommended approach for insulin management in patients with diabetes?
What is the incidence of septic shock and mortality in adult intensive‑care or medical‑surgical patients with a retained central‑line catheter who develop a central line‑associated bloodstream infection (CLABSI)?
Should a patient with a random blood glucose of 300 mg/dL be discharged on sliding‑scale insulin alone with insulin glargine (Lantus) 25 units?
In a 38‑year‑old man with a prior lateral sphincterotomy and mild pelvic‑floor hypertonicity who underwent a fistulotomy that healed the fistula but increased pelvic‑floor pain and bladder‑sensory changes without causing incontinence, was the fistulotomy a clinical error, does the risk of a repeat sphincter‑preserving procedure such as ligation of the intersphincteric fistula tract (LIFT) outweigh its benefit, and can biofeedback therapy still be effective for his hypertonicity?
What is a comprehensive lifestyle and pharmacologic protocol for an adult with overweight/obesity, insulin resistance, pre‑diabetes or early type 2 diabetes, dyslipidemia, and hypertension?
What is the evidence for augmenting levothyroxine (LT4) with liothyronine (T3) in hypothyroidism, and which patients are appropriate candidates?
What is the recommended adult dose of oseltamivir (Tamiflu) for treating influenza B and for post‑exposure prophylaxis, and how should it be adjusted in patients with creatinine clearance ≤30 mL/min?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.